Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.

The PROPHET assay, which sequences 50 patient-specific variants, was compared with fixed-panel assays in 760 plasma samples from 181 people with early-stage non-small cell lung cancer.

Cancer CellPubMed 37683638DOI 10.1016/j.ccell.2023.08.010